Categories: News

Panacea Life Sciences Holdings, Inc. Announces Participation in Investor Summit Group’s Q2 In-Person Conference

GOLDEN, CO / ACCESSWIRE / May 3, 2022 / Panacea Life Sciences Holdings, Inc. (OTCQB:PLSH) is pleased to announce that Leslie Buttorff will be in attendance at The Q2 Investor Summit Group – In-Person. Panacea Life Sciences Holdings’ Chief Executive Officer, Leslie Buttorff, will discuss the company’s roadmap for growth in the next 1-2 years.

Event:

The Q2 Investor Summit Group

Date:

May 3-4, 2022

Location:

The Westin New York Grand Central
212 E 42nd St, New York, NY 10017

Presentation:

May 3rd at 1:15PM ET

View webcast presentation:

https://newsroom.panacealife.com

About Panacea Life Sciences Holdings, Inc.

Panacea Life Sciences Holdings, Inc. (OTCQB:PLSH) is a fully integrated FDA, cGMP certified, seed-to-sale cannabinoid product focused company. We research, develop, manufacture and commercialize raw materials derived from industrial hemp and custom formulate, manufacture and distribute softgels (both bovine and vegan), gummies, tinctures, sublingual tablets, patches, K-Tape, topical pain relief and skin care products as our base business. We have expanded our research and development preclinical and clinical programs, with a focus on nutraceutical and purposeful, natural pharmaceutical alternatives for humans and companion animals. We research, produce, and distribute products both domestically and internationally that target and treat major categories of medical conditions: pain, cancer, psychological, epilepsy, gastrointestinal, autoimmune, neurological, and sleep disorders and support these product through clinical research and studies. These categories include conditions that affect hundreds of millions of patients and animals worldwide.Our vision is to become the leading research and manufacturing cannabinoid and nutraceutical company (top 10 in terms of revenue and brand) in the U.S.

For further information:

Panacea Life Sciences Holdings, Inc.
Leslie Buttorff
3034340215
leslie.buttorff@panacealife.com

About the Investor Summit Group

The Investor Summit Group (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. The Q2 Investor Summit Group will take place in-person, featuring 65+ companies and over 300 investors comprising institutional investors, family offices, and high net worth investors. Sectors Participating: Biotech, Communication Services, Consumer, Energy, Energy/Tech, Financial, Healthcare, Industrials, Materials, Real Estate, Technology, and Tech/Crypt. info@investorsummitgroup.com

SOURCE: Panacea Life Sciences, Inc

View source version on accesswire.com:
https://www.accesswire.com/699840/Panacea-Life-Sciences-Holdings-Inc-Announces-Participation-in-Investor-Summit-Groups-Q2-In-Person-Conference

Staff

Recent Posts

Senseonics Holdings, Inc. Provides Business Update and Full Year 2024 Financial Outlook

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the…

48 mins ago

Safe Supply Streaming Corp. Announces Resignation of Board Member

Toronto, Ontario--(Newsfile Corp. - June 21, 2024) - Safe Supply Streaming Co Ltd. (CSE: SPLY) (FSE:…

51 mins ago

NuGen Announces Initial Purchase Order from Sol-Millennium(TM) for Pharmacy Launches in the Canadian and European Markets

Toronto, Ontario--(Newsfile Corp. - June 21, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the…

51 mins ago

Cryo Sculpting Lab Announces Revolutionary Franchise Opportunity in Non-Invasive Body Contouring

SAN DIEGO, June 21, 2024 /PRNewswire/ -- Cryo Sculpting Lab (CSL), a pioneer in non-invasive…

51 mins ago

Service Coordination Awarded Washington Post 2024 Top Workplace Honor

FREDERICK, Md., June 21, 2024 /PRNewswire/ -- Service Coordination Inc. (SCI), a leading provider of…

51 mins ago

Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders

Jaguar to report pivotal phase 3 OnTarget trial results for its cancer supportive care drug…

51 mins ago